{"id":"W2093055119","doi":"10.1002/cncr.23880","title":"Phase 2 trial of rituximab plus hyper‐CVAD alternating with rituximab plus methotrexate‐cytarabine for relapsed or refractory aggressive mantle cell lymphoma","year":2008,"lang":"en","type":"article","venue":"Cancer","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Mantle cell lymphoma; Cytarabine; Rituximab; Internal medicine; Neutropenia; Vincristine; Regimen; Gastroenterology; Cyclophosphamide; Febrile neutropenia; Surgery; Phases of clinical research; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00183038,0.001502945,0.001626726,0.0004438247,0.0003549833,0.0009328977,0.001110007,0.001171961,0.003954866],"category_scores_gemma":[0.001040683,0.0005766453,0.0006798799,0.0003658238,0.0008600611,0.0007264107,0.0003427978,0.002964088,0.0008535998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007228777,"about_ca_system_score_gemma":0.001190674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000750708,"about_ca_topic_score_gemma":0.001460871,"domain_scores_codex":[0.9994325,0.0003702884,0.00001904709,0.00007825356,0.0000411019,0.00005877937],"domain_scores_gemma":[0.9993319,0.0001439169,0.0001350592,0.0000713323,0.00003894741,0.0002787642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8074028,0.0736618,0.004275129,0.0005819451,0.001165864,0.0002561964,0.0003213659,0.00222148,0.02351563,0.0002814025,0.002863622,0.08345272],"study_design_scores_gemma":[0.7701184,0.2228938,0.003599664,0.0000193892,0.0001808785,0.0001430673,0.00002089835,0.0008605213,0.0009933311,0.00009230796,0.001063527,0.00001418536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945127,0.001214243,0.000440309,0.0003735826,0.0001168893,0.001680269,0.000395443,0.00008016489,0.00118646],"genre_scores_gemma":[0.9899477,0.00106163,0.001991153,0.0008584617,0.0002814013,0.00259187,0.001373227,0.00002746946,0.001867093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003954866,"threshold_uncertainty_score":0.01323032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05489979543989888,"score_gpt":0.3455933434722654,"score_spread":0.2906935480323666,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}